-
THE COST-EFFECTIVENESS ANALYSIS OF INATICABTAGENE AUTOLEUCEL FOR RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS IN CHINA
Mar 18, 2026, 21:38 PM -
THE BUDGET IMPACT OF INTRODUCING ZONGERTINIB INTO THE FORMULARY FOR TREATMENT-NAÏVE AND PRETREATED HER2-MUTANT ADVANCED NSCLC IN THE UNITED STATES
Mar 18, 2026, 21:38 PM -
EFFECT OF CHINESE HERBAL MEDICINE COMBINED WITH CONVENTIONAL ANTI-OSTEOPOROTIC MEDICATION ON FRACTURE RISK IN OLDER ADULTS WITH OSTEOPOROSIS: A RETROSPECTIVE COHORT STUDY
Mar 18, 2026, 21:38 PM -
COMPARATIVE EFFECTIVENESS OF SGLT2I, GLP-1, AND METFORMIN ON CARDIOVASCULAR OUTCOMES IN ADULTS WITH SEVERE MENTAL ILLNESS
Mar 18, 2026, 21:38 PM -
SURVIVING UNANCHORED INDIRECT COMPARISONS: AN EXTENSION OF MULTILEVEL UNANCHORED META-REGRESSION (ML-UMR) FOR SURVIVAL ANALYSES
Mar 18, 2026, 21:38 PM -
ARE EVIDENCE REVIEW REQUIREMENTS SIMILAR ACROSS HEALTH TECHNOLOGY ASSESSMENT (HTA) AGENCIES? A CROSS-SECTIONAL STUDY OF NICE, CDA, IQWIG AND EU JCA
Mar 18, 2026, 21:38 PM -
TRENDS IN THE USE OF REAL-WORLD EVIDENCE IN PRESS RELEASES ISSUED BY THE TOP 15 PHARMACEUTICAL COMPANIES
Mar 18, 2026, 21:38 PM -
BUDGET IMPACT OF FINERENONE IN HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF) AND HEART FAILURE WITH MILDLY REDUCED EJECTION FRACTION (HFMREF):IMPLICATIONS FOR U.S. HEALTHCARE DECISION-MAKERS
Mar 18, 2026, 21:38 PM -
HEALTHCARE COST, RESOURCE USE, AND ECONOMIC MODELS OF CISPLATIN-INELIGIBLE MUSCLE-INVASIVE BLADDER CANCER PATIENTS (MIBC)
Mar 18, 2026, 21:38 PM -
USE OF REAL-WORLD EVIDENCE ON US BRANDED HCP DRUG WEBSITES: AN AI-ENABLED CONTENT ANALYSIS
Mar 18, 2026, 21:38 PM -
TEMPORAL TRENDS AND DETERMINANTS OF AORTIC VALVE REPLACEMENT IN PATIENTS WITH ASYMPTOMATIC SEVERE AORTIC STENOSIS
Mar 18, 2026, 21:38 PM -
COMPARISON OF SAMPLING STRATEGIES TO ADDRESS SEVERE DATA IMBALANCE AND COMPUTATIONAL BENCHMARKING FOR TIME-TO-EVENT PREDICTIVE MODEL DEVELOPMENT ACROSS LOCAL AND HIGH-PERFORMANCE COMPUTING ENVIRONMENTS: PREDICTION OF ALCOHOL USE DISORDER AND OPIOID...
Mar 18, 2026, 21:38 PM -
PROJECT ORBIS: DOES REGULATORY ACCELERATION TRANSLATE TO FASTER GLOBAL PATIENT ACCESS?
Mar 18, 2026, 21:38 PM -
WHEN ADHERENCE ESTIMATES DIFFER: THE IMPACT OF DATA SOURCE AND GAP HANDLING IN REAL-WORLD MEDICATION USE ASSESSMENT
Mar 18, 2026, 21:38 PM -
EVALUATING THE IMPACT OF THE INFLATION REDUCTION ACT OUT-OF-POCKET CAPS ON PATIENT ASSISTANCE FUNDS EFFICIENCY AND COVERAGE EXPANSION
Mar 18, 2026, 21:38 PM -
HEALTHCARE RESOURCE UTILIZATION AND COSTS OF DIABETES MELLITUS: A RETROSPECTIVE REAL-WORLD COST-OF-ILLNESS ANALYSIS IN BRAZIL
Mar 18, 2026, 21:38 PM -
ENABLING HEALTH TECHNOLOGY ASSESSMENT (HTA) TA READINESS THROUGH REAL-TIME AI-ASSISTED LIVING SYSTEMATIC LITERATURE REVIEWS (REAL-SLR): A BREAST CANCER (BCA) CASE STUDY
Mar 18, 2026, 21:38 PM -
MACHINE LEARNING EVALUATION OF RACIAL AND ETHNIC INCLUSION UNDER ALTERNATIVE COST-BASED APPROACHES TO MEDICARE MEDICATION THERAPY MANAGEMENT ELIGIBILITY
Mar 18, 2026, 21:38 PM -
AI-ASSISTED APPROACHES FOR DEFINING LINES OF THERAPY IN ONCOLOGY REAL-WORLD DATA: AN EXPLORATORY ANALYSIS IN CHRONIC LYMPHOCYTIC LEUKEMIA
Mar 18, 2026, 21:38 PM -
COST-EFFECTIVENESS OF LAZERTINIB-AMIVANTAMAB COMPARED TO OSIMERTINIB FOR NON-SMALL CELL LUNG CANCER: A 5-YEAR PARTITIONED SURVIVAL MODEL
Mar 18, 2026, 21:38 PM
